Nature Reviews Cancer Submission Process

Initial Quality Check

This is where the editor can see whether the submission is a real proposal: 200-word abstract, main sections, key references, author list, affiliations, disclosures, and any figures or outline material requested. Confirm authorship, conflict-of-interest disclosures, ethics or permissions notes where relevant, plagiarism-safe reference handling, checklist completeness, and data or figure-source permissions before submission.

Editorial Assignment

The editor decides whether the idea belongs with Nature Reviews Cancer or a narrower oncology review journal. This is not only a topic check; it is also a commissioning-priority and author-position check.

Editorial Evaluation

The professional editorial team tests whether the piece will synthesize a field rather than summarize papers. A strong synopsis shows the argument architecture before a full manuscript is polished.

Peer Review

If the article moves to review, reviewers usually pressure-test authority, balance, omitted competing models, clinical or therapeutic interpretation, and whether the figures clarify the field. Nature Portfolio offers double-blind peer review across its journals, and review-type articles can also move through conventional expert peer review depending on the journal workflow and author choices.

Final Decision

The final decision turns on whether the article still feels like a Nature Reviews Cancer synthesis after editorial and reviewer scrutiny, not whether the topic is merely publishable somewhere.

This page is about workflow after a concept or manuscript is in editorial hands.

Use it when you want to understand:

• what editors are judging first after a pitch or submission lands

• what deeper editorial handling usually means

• how to interpret silence, delay, or stalled momentum

• where review-led oncology concepts usually fail before external review matters

If you still need to decide whether Nature Reviews Cancer is the right journal at all, use the verdict page. If the question is whether the concept is strong enough before you pitch it, use the submission guide.

We reviewed the Nature Reviews Cancer author instructions, journal information page, aims and scope, publishing model, and recent journal content. We also reviewed the 100 most recent journal papers used when this guide was built and recent manuscripts looking to submit to this journal through Manusights pre-submission reviews. The point of this page is not to repeat the official instructions. It is to show the editorial triage pattern those instructions imply.

Recent Nature Reviews Cancer article anchors we checked included reviews and comments such as "Neuro-immune cross-talk in cancer" (10.1038/s41568-025-00831-w), "Targeted protein degradation for cancer therapy" (10.1038/s41568-025-00817-8), and "Regulatory T cells in the tumour microenvironment" (10.1038/s41568-025-00832-9). We used those not as templates to copy, but as examples of the article posture the journal tends to reward: selective synthesis, strong framing, and clear display logic.

Before submitting to Nature Reviews Cancer, a Nature Reviews Cancer submission-readiness check identifies whether the package meets the editorial bar before you commit to the submission.

This guide tells you what Nature Reviews Cancer editors look for in the public submission process; the review tells you whether your paper passes that screen. Manusights reviewers have reviewed 35+ oncology manuscripts and review concepts, full reviews include a 60-day money-back guarantee, and we do not train models on your manuscript.

• The synopsis lacks a field-level argument. The proposal names a cancer topic but does not show what disagreement, model, therapeutic direction, or clinical question the article will reorganize.

• The author team does not prove editorial authority. The affiliations and publication record may be credible, but the package does not show why these authors should lead this exact synthesis.

• The display-item plan summarizes literature instead of creating a framework. Figures and tables list mechanisms, trials, or targets without helping readers understand the field differently.

• Treating the journal like a standard unsolicited review destination.

• Submitting a review that is really a narrow subtopic memo.

• Summarizing literature without making a clear conceptual argument.

• Ignoring therapeutic or clinical implications in a cancer review journal.

• Using a cover note that says little more than the abstract.

• Failing to explain why this piece belongs here instead of in a strong but less selective review journal.

Check whether your Nature Reviews Cancer synopsis has a field-level argument ->

Check your author-position and authority signal ->

Check if your figures create a review framework ->

Editors will immediately ask whether the article defines a major cancer question or therapeutic direction with enough clarity. If the opening feels diffuse, the whole package feels less serious.

This journal cares about whether the authors look credible to write the review. If the manuscript does not feel anchored in recognized expertise, the process becomes harder.

Nature Reviews Cancer is not looking for a reference list in paragraph form. Editors and reviewers want:

• competing models weighed honestly

• field disagreements made explicit

• clinical consequences discussed carefully

• future research directions stated with judgment

Even a mechanism-heavy review should tell the reader why the biology matters. If the review never gets to therapeutic relevance, biomarkers, disease strategy, or translational stakes, it often feels incomplete for this journal.

The strongest proposal materials usually explain:

• the exact field gap the review will address

• why the topic is timely now

• why the authors are credible to lead the synthesis

• how the article will go beyond a standard review

• what readers will understand differently after reading it

That is much more persuasive than sending a generic note that says the topic is important.

Many authors approach this journal as though the process begins with a finished manuscript. In reality, the more realistic route often starts by deciding whether the idea itself is likely to interest the editors before investing heavily in the final full package.

For an unsolicited review concept, the practical questions are:

• is the field inflection point clear enough to justify a major review now

• does the article have obvious clinical, therapeutic, or translational stakes

• will the review help readers reorganize a field, not just catch up on it

• are the authors well placed to write it

If the answer to any of those is uncertain, the best decision may be to redirect the article to a strong oncology review journal with a more conventional unsolicited pathway.

That is not a defeat. It is usually a better submission decision than spending months polishing a package that never really matched the editorial bar here.

It also gives the author team a cleaner chance to publish while the synthesis is still timely, rather than losing momentum inside an overly ambitious targeting strategy.

Of the 100 recent Nature Reviews Cancer papers we reviewed when this guide was built, the strongest pattern was not article polish. It was editorial posture. The article usually had a clear field-level question, a selective reference spine, and display-item logic that helped readers understand the field differently.

Across Manusights submission reviews for oncology manuscripts and review concepts, Manusights review data shows the same pattern. The drafts that feel viable usually make two things obvious immediately: the review is reorganizing a field rather than summarizing it, and the author team is plausibly positioned to lead that synthesis. The weak concepts are often well written but too narrow, too descriptive, or too detached from real translational stakes to justify this journal's editorial attention.

Editors specifically screen for the difference between "this is a good review topic" and "this is a Nature Reviews Cancer article." That difference usually lives in the synopsis, not in the final copyedit.

The synopsis reads like a topic summary, not an editorial argument

For Nature Reviews Cancer, the 200-word synopsis has to do more than announce a cancer topic. It should define the field-level tension, name the literatures being integrated, and show why this review would help readers make sense of the area now. If the synopsis could introduce a routine review in several oncology journals, the package is not yet strong enough for this route.

The author list does not make field leadership obvious

For a review-led Nature title, author authority is part of the submission process. The editor needs to see why this team can synthesize the field, weigh competing evidence, and set a useful agenda. A locally credible author list can still look weak if no one is visibly positioned around the exact cancer mechanism, therapeutic direction, or clinical question being reviewed.

The display items summarize papers instead of creating a framework

Nature Reviews Cancer figures and tables usually need to teach the field, not decorate the article. If the proposed display items only list pathways, trials, targets, or mechanisms, the editor has less evidence that the article will reorganize the topic. Stronger packages use display logic to compare models, connect mechanism to therapy, or expose a decision structure for future work.

Use official guidance for live portal mechanics. For Nature Reviews Cancer submission process, the Manusights decision layer separates administrative upload steps from the fit, evidence, authorship, reviewer, or public-review problems that surface before the manuscript reaches an editor.